Dana-Farber Cancer Care Collaborative

DFCI-collab-graphic-for-web.pngEMMC Cancer Care, located at the Lafayette Family Cancer Center, is the newest member of the Dana-Farber Cancer Care Collaborative. Participation in the Collaborative reflects a demonstrated commitment to excellence by meeting a wide array of standards and best practices.

As part of the membership process, Dana-Farber Cancer Institute clinicians and other specialists conducted an extensive review of EMMC Cancer Care’s outpatient adult medical oncology practices and procedures, including patient safety protocols, nursing and pharmacy practices, chemotherapy administration, and information systems. Membership in the collaborative enhances educational opportunities for staff, and offers opportunities for consultation with medical specialists at Dana-Farber in Boston for complex cases. In addition, many of the latest Dana-Farber clinical trials will be available in Maine for patients at EMMC Cancer Care.

“This collaboration will benefit our patients, staff, and community,” said Deborah Carey Johnson, RN, CEO of Eastern Maine Medical Center. “To be recognized for our quality of care by an institution like Dana-Farber Cancer Institute is also a testament to the quality of care provided by our team. They’re truly a remarkable group.”

“Our mission is to help relieve the burden of cancer for as many people as possible,” said Laurie Glimcher, MD, president and CEO of Dana-Farber Cancer Institute. “We do this by conducting research to develop better therapies, by providing expert and compassionate care for our patients, and by working with other carefully selected care providers. We are very pleased to welcome this important new member of the Dana-Farber Cancer Care Collaborative and look forward to our work together.”

Dana-Farber Cancer Care Collaborative was established to help disseminate the latest and most effective, evidence-based best practices and standards to member hospitals and physician practices. Members undergo a rigorous review of their oncology operations, and agree to implement key recommendations to meet Dana-Farber standards. Members also take advantage of ongoing consultations and access to support services, such as on-site specialty second opinion clinics, clinical trials, tumor board conferences and physician lectures.